{"gene":"IRF6","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":2002,"finding":"IRF6 encodes a transcription factor with a helix-turn-helix DNA-binding domain and a protein-binding domain; loss-of-function (haploinsufficiency) mutations cause Van der Woude syndrome and dominant-negative mutations cause popliteal pterygium syndrome, establishing IRF6 as required for orofacial and skin development. Expression analyses showed high Irf6 mRNA in medial edge epithelium of fusing palate, tooth buds, hair follicles, genitalia, and skin.","method":"Mutation identification by sequencing, expression analysis by in situ hybridization","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — seminal loss-of-function genetics with expression data, widely replicated","pmids":["12219090"],"is_preprint":false},{"year":2011,"finding":"A conserved Pbx-Wnt-p63-Irf6 regulatory module controls midfacial ectoderm development; Pbx proteins bind a midfacial regulatory element to drive Wnt9b-Wnt3 expression, which in turn regulates p63 and thereby Irf6, promoting epithelial apoptosis required for facial process fusion. Loss of Pbx in cephalic ectoderm suppresses midfacial apoptosis and causes cleft lip/palate, rescued by ectopic Wnt expression.","method":"Conditional knockout mice, ChIP, transgenic rescue experiments","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with ChIP and in vivo rescue, moderate evidence","pmids":["21982646"],"is_preprint":false},{"year":2011,"finding":"IRF6 acts as a tumor suppressor in squamous cell carcinoma (SCC): it is transcriptionally activated by p63 and induces proteasome-mediated downregulation of p63, limiting keratinocyte proliferative potential. ChIP-seq and expression profiling identified direct IRF6 target genes regulating cell cycle, differentiation, adhesion, and cell-cell contact. IRF6 reintroduction into SCC cells strongly inhibits cell growth and invasiveness.","method":"ChIP-seq, siRNA knockdown, gene expression profiling, in vitro invasion assays, promoter methylation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP-seq, expression profiling, functional assays) in a single study","pmids":["21807998"],"is_preprint":false},{"year":2011,"finding":"IRF6 is a primary Notch transcriptional target in keratinocytes; Notch activation induces IRF6 expression, and IRF6 is required for the pro-differentiation and tumor suppressive effects of Notch signaling. IRF6 downmodulation counteracts keratinocyte differentiation in vitro and in vivo and promotes ras-induced tumor formation.","method":"Reporter assays, siRNA knockdown, in vivo differentiation assays, tumor formation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods with in vivo validation","pmids":["21909072"],"is_preprint":false},{"year":2009,"finding":"IRF6 and the Notch ligand Jagged2 function in convergent molecular pathways to control oral epithelial differentiation and periderm formation; IRF6 is essential for maintaining oral periderm integrity, spatiotemporal regulation of which determines appropriate palatal adhesion. Loss of Irf6 in mice leads to abnormal oral epithelial differentiation and pathological adhesion between palatal shelves and tongue.","method":"Mouse knockout analysis, tissue histology, in situ hybridization, genetic interaction studies","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — clean knockout with defined cellular and molecular phenotype, replicated findings","pmids":["19439425"],"is_preprint":false},{"year":2019,"finding":"RIPK4 kinase phosphorylates IRF6 at Ser413 and Ser424, priming IRF6 for transcriptional activation. IRF6 and RIPK4 regulate overlapping biological processes in epidermal differentiation. IRF6 was enriched at bivalent promoters and its deficiency caused defective expression of genes involved in lipid metabolism and tight junction formation, resulting in abnormal stratum corneum lipid composition and severe epidermal barrier defect.","method":"RNA-seq, ChIP-seq, ATAC-seq of wild-type and IRF6-deficient mouse embryo skin, phosphorylation site mutagenesis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1/2 — multi-omic approach with mutagenesis and in vivo validation","pmids":["31578523"],"is_preprint":false},{"year":2014,"finding":"RIPK4-deficient mice display epithelial fusions associated with abnormal periderm development and aberrant ectopic E-cadherin localization on the apical peridermal membrane. In Xenopus, IRF6 controls RIPK4 expression, and wild-type but not kinase-dead RIPK4 rescues gastrulation defects caused by dominant-negative IRF6. RIPK4 plays a role in cortical actin cytoskeleton organization in mouse epidermis and human HaCaT epithelial cells.","method":"Mouse and Xenopus knockdown/overexpression, rescue experiments with kinase-dead RIPK4, immunofluorescence for E-cadherin and actin","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple species, epistasis experiments, kinase-dead rescue distinguishes mechanism","pmids":["25430793"],"is_preprint":false},{"year":2013,"finding":"TGFβ signaling via SMAD4 regulates IRF6 expression and MEE fate during palatal fusion. Haploinsufficiency of Irf6 in mice with Smad4 deletion in basal epithelium results in MEE persistence; overexpression of Irf6 rescues p21 expression and MEE degeneration in Tgfbr2-deficient mice, placing IRF6 downstream of TGFβ/SMAD4 in palatal fusion.","method":"Conditional knockout mice, genetic epistasis, in vivo Irf6 overexpression rescue experiments, p21 expression analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — epistasis confirmed with rescue experiment in two genotypes","pmids":["23406900"],"is_preprint":false},{"year":2015,"finding":"IRF6 phosphorylation by RIPK4 at Ser413 and Ser424 induces IRF6 transactivation function; the VWS-associated p.Arg412X truncation causes rapid proteasome-dependent IRF6 degradation and prevents RIPK4-induced transactivation. The BPS-associated RIPK4 p.Ser376X mutation impairs RIPK4 induction of IRF6 transactivator function and also inhibits RIPK4-mediated β-catenin stabilization.","method":"Transfection with mutant constructs, proteasome inhibition assay, reporter assays for transactivation, co-expression experiments","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis with functional readouts for both IRF6 and RIPK4 disease mutations","pmids":["25784454"],"is_preprint":false},{"year":2015,"finding":"TGFβ3 increases IRF6 expression, which subsequently upregulates SNAI2 (an EMT regulator) and downregulates epithelial markers (E-cadherin, Plakophilin, ZO-1), promoting epithelial-mesenchymal transition during palatal fusion. Blocking SNAI2 delays palatal fusion and abolishes the IRF6 rescue effect, placing SNAI2 downstream of IRF6 in TGFβ3-mediated palatogenesis.","method":"Palatal shelf organ culture, siRNA knockdown, ectopic IRF6 overexpression, immunofluorescence for EMT markers","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — ex vivo system with overexpression and knockdown, single lab","pmids":["26240017"],"is_preprint":false},{"year":2015,"finding":"IRF6 acts downstream of IRAK1 (IL-1R-associated kinase 1) in TLR2 signaling to stimulate IL-36γ expression in human oral epithelial cells in response to Porphyromonas gingivalis. Gene silencing and promoter assays demonstrated IRF6 directly regulates IL-36γ promoter activity.","method":"siRNA gene silencing, gene promoter reporter assays, TLR2 agonist stimulation","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2/3 — epistasis and promoter assays from single lab","pmids":["26819203"],"is_preprint":false},{"year":2015,"finding":"IRF6 regulates TLR3-dependent IL-23p19 expression in human keratinocytes; IRF6 silencing enhances poly(IC)-inducible IFN-β and inhibits IL-23p19 expression. Overexpression of IRF6 increases IL-23p19 promoter activity but inhibits IFN-β promoter activity. IL-23p19 and EBI3 interact (forming a novel heterodimer) as shown by co-immunoprecipitation and proximity ligation assays.","method":"siRNA silencing, reporter assays, co-immunoprecipitation, proximity ligation assay","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 2/3 — multiple methods from single lab, IP confirmed by proximity ligation","pmids":["26303210"],"is_preprint":false},{"year":2016,"finding":"RIPK4 and IRF6 function as a signaling axis in keratinocytes to regulate proinflammatory cytokine expression; RIPK4 overexpression specifically induces CCL5 and CXCL11 through IRF6-mediated transactivation of their promoters. Gene silencing confirmed that inducible CCL5 and CXCL11 expression requires both RIPK4 and IRF6.","method":"Overexpression, siRNA silencing, gene reporter assays","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2/3 — consistent with RIPK4-IRF6 axis, reporter assays plus knockdown, single lab","pmids":["27014863"],"is_preprint":false},{"year":2014,"finding":"A mutation (350dupA) in the conserved IRF6 enhancer element MCS9.7 abrogates p63 and E47 binding to overlapping cis-motifs and disrupts enhancer activity; additionally, the mutation creates a CAAAGT Lef1 binding site that enables Lef1/β-Catenin to repress MCS9.7 enhancer activity, demonstrating a dual loss- and gain-of-function mechanism at the IRF6 regulatory element.","method":"Luciferase reporter assays in human cell cultures, transgenic mouse lacZ reporter assay, EMSA/binding assays for p63, E47, and Lef1","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1/2 — reporter assays plus transgenic mouse validation plus binding assays","pmids":["24442519"],"is_preprint":false},{"year":2018,"finding":"HPV16 E6 oncoprotein inhibits IRF6 transcription by degrading p53, which normally binds the IRF6 promoter to drive its expression. IRF6 in turn regulates IL-1β promoter activity in human keratinocytes. HPV16 thus exploits p53 degradation to suppress IRF6 and block IL-1β production as an immune evasion mechanism.","method":"siRNA against E6, E6 point mutants preventing p53 degradation, ChIP for p53 at IRF6 promoter in cervical cancer tissues, IRF6 promoter reporter assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — ChIP in patient tissues plus mutant E6 rescue plus reporter assays","pmids":["30089163"],"is_preprint":false},{"year":2019,"finding":"Over-expression of Irf6 in mice causes exencephaly by suppressing Tfap2a and Grhl3 expression; conversely, loss of Irf6 reduces Tfap2a and Grhl3 in tail tissues and causes a curly tail phenotype, establishing Irf6 within a Tfap2a-Irf6-Grhl3 genetic pathway conserved in both orofacial and neural tube morphogenesis.","method":"Irf6 overexpression and loss-of-function mouse models, expression analysis of Tfap2a and Grhl3, human spina bifida sequencing","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with expression data, bidirectional manipulation","pmids":["30689861"],"is_preprint":false},{"year":2017,"finding":"Loss of Irf6 causes craniosynostosis and mandibular hypoplasia; Irf6 and Twist1 interact genetically (double heterozygotes have severe mandibular hypoplasia/agnathia), with reduced EDN1 and downstream DLX5, DLX6, HAND2 expression in mesenchymal cells. Exogenous EDN1 peptides partially rescue Meckel's cartilage abnormalities, and partial rescue also occurs with p53 haploinsufficiency.","method":"Double heterozygous mouse crosses, spatiotemporal expression analysis, mandibular explant treatment with EDN1, p53 genetic rescue","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic interaction with molecular pathway readouts and partial rescue","pmids":["28769044"],"is_preprint":false},{"year":2024,"finding":"EMT transcription factors ZEB1 and SNAIL epigenetically and transcriptionally silence IRF6 during acquired resistance to immunotherapy in pancreatic ductal adenocarcinoma. IRF6 silencing renders tumor cells less sensitive to TNF-α-mediated pro-apoptotic effects, establishing a tumor cell-intrinsic mechanism of resistance distinct from immune evasion.","method":"Mouse PDAC immunotherapy resistance model, RNA-seq, ChIP/epigenetic analysis, functional TNF-α killing assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — mechanistic model with multiple orthogonal methods and in vivo relevance","pmids":["38378697"],"is_preprint":false},{"year":2012,"finding":"Irf6 mutant mice show evagination (rather than invagination) of incisor epithelium similar to Ikkα mutants, with upregulation of canonical Wnt signaling in evaginated incisor epithelium; IRF6 regulates epithelial invagination in an NF-κB-independent manner.","method":"Irf6 mouse mutant analysis, in situ hybridization, immunohistochemistry for Wnt pathway components and NF-κB","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — clean knockout phenotype with molecular pathway analysis, single lab","pmids":["22366192"],"is_preprint":false},{"year":2020,"finding":"SPECC1L expression is drastically reduced in Irf6 mutant palatal shelves, and SPECC1L deficiency causes periderm layer abnormalities similar to Irf6 hypomorphic mutants, placing SPECC1L downstream of IRF6 in palatogenesis. SPECC1L mutations that disrupt microtubule association are linked to syndromic CL/P.","method":"Irf6 mutant mouse expression analysis, conditional Specc1l knockout mouse, epistasis by genetic cross, immunofluorescence","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — expression epistasis in mutant background confirmed by genetic cross","pmids":["31943082"],"is_preprint":false},{"year":2008,"finding":"IRF6 was identified as a binding partner of maspin in mammary epithelial cells; IRF6 functions synergistically with maspin to regulate mammary epithelial cell differentiation by acting on the cell cycle, promoting exit from the cell cycle and entry into G0 quiescence.","method":"Protein interaction studies, cell cycle analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Low","confidence_rationale":"Tier 3 — review/perspective with limited primary experimental detail provided in abstract","pmids":["18604160"],"is_preprint":false},{"year":2016,"finding":"Conditional ablation of Irf6 in late embryonic oral epithelium results in dysplastic salivary glands with disrupted epithelial junctional complexes (associated with elevated RHO GTPase activation), increased salivary cell proliferation, reduced saliva flow and buffering capacity, decreased CCL27 expression, and increased colonization by cariogenic bacteria.","method":"Conditional Irf6 knockout mouse (oral epithelium-specific), histology, RHO GTPase activity assay, saliva flow measurement, bacterial colonization assay","journal":"Journal of dental research","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific knockout with multiple molecular and functional readouts","pmids":["27927890"],"is_preprint":false},{"year":2017,"finding":"Human IRF6 missense variant protein function can be assessed by ability to rescue the irf6-/- periderm rupture phenotype in zebrafish via mRNA microinjection; many variants predicted computationally to be loss-of-function retained partial or full protein function, enabling grouping into wild-type function, reduced function, and complete loss-of-function categories.","method":"Zebrafish irf6-/- rescue with human IRF6 variant mRNA microinjection, mRNA dosage titration","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo functional assay in zebrafish model with dosage titration","pmids":["28945736"],"is_preprint":false},{"year":2020,"finding":"Lin28A stabilizes lncRNA SNHG14, which promotes IRF6 mRNA degradation by targeting its 3' UTR via STAU1-mediated mRNA decay; this reduces IRF6 expression and consequently relieves IRF6-mediated transcriptional repression of PKM2 and GLUT1, thereby promoting aerobic glycolysis in glioma cells.","method":"RNA stability assays, siRNA knockdown, mRNA interaction assays, xenograft tumor models, ChIP/promoter assays for PKM2 and GLUT1","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2/3 — multiple methods but complex indirect regulatory cascade; single lab","pmids":["32527996"],"is_preprint":false},{"year":2015,"finding":"IRF6 is involved in cell proliferation and transformation in MCF10A breast epithelial cells downstream of Notch signaling; ΔNp63 downregulation by Notch contributes to IRF6 expression, and IRF6 abrogation impairs Notch-induced proliferation and transformation, demonstrating a context-dependent role for IRF6 as a positive regulator of proliferation downstream of Notch in these cells.","method":"siRNA knockdown, Notch activation, proliferation and transformation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, knockdown with proliferation phenotype; context-specific result","pmids":["26161746"],"is_preprint":false}],"current_model":"IRF6 is a transcription factor that is activated downstream of p63 (via the MCS9.7 enhancer), Notch, and TGFβ/SMAD4 signaling; it is phosphorylated by RIPK4 at Ser413/424 to prime its transactivation function, enabling IRF6 to drive keratinocyte and epithelial differentiation programs (including lipid metabolism, tight junction, and periderm gene expression), regulate cell cycle exit, suppress EMT-driven tumor cell resistance, and control inflammatory cytokine production (IL-36γ, CCL5, CXCL11, IL-1β), while a reciprocal feedback loop whereby IRF6 induces proteasome-mediated p63 degradation limits keratinocyte proliferative potential."},"narrative":{"teleology":[{"year":2002,"claim":"Identifying the causative gene for Van der Woude and popliteal pterygium syndromes established that a member of the IRF transcription factor family has a non-immune, developmental role in orofacial and skin morphogenesis.","evidence":"Mutation screening and in situ hybridization in affected families and mouse embryos","pmids":["12219090"],"confidence":"High","gaps":["DNA-binding targets unknown","mechanism of action in epithelial differentiation uncharacterized","post-translational regulation unknown"]},{"year":2009,"claim":"Demonstrating that Irf6 knockout mice have defective oral periderm integrity and pathological epithelial adhesions defined the cellular basis of IRF6's role in palatogenesis — maintaining a specialized surface epithelium (periderm) that prevents inappropriate tissue fusion.","evidence":"Irf6 knockout mouse phenotyping, histology, and genetic interaction with Jagged2","pmids":["19439425"],"confidence":"High","gaps":["Direct transcriptional targets mediating periderm formation not identified","relationship between IRF6 and Notch pathway only inferred from parallel phenotypes"]},{"year":2011,"claim":"Three studies converged to place IRF6 within interconnected signaling cascades: a Pbx–Wnt–p63–Irf6 module controlling midfacial morphogenesis, Notch signaling directly inducing IRF6 for keratinocyte differentiation and tumor suppression, and a reciprocal feedback loop in which p63 activates IRF6, which then triggers proteasomal p63 degradation to enforce cell cycle exit.","evidence":"Conditional knockout mice with ChIP and rescue (Pbx–Wnt); siRNA knockdown with in vivo differentiation and tumor assays (Notch); ChIP-seq, expression profiling, and invasion assays in SCC cells (p63 feedback)","pmids":["21982646","21909072","21807998"],"confidence":"High","gaps":["Direct versus indirect Notch regulation of IRF6 promoter not fully resolved","genome-wide target overlap between Notch-driven and p63-driven IRF6 programs not compared","structural basis of IRF6–proteasome coupling to p63 degradation unknown"]},{"year":2013,"claim":"Genetic epistasis and rescue experiments placed IRF6 downstream of TGFβ/SMAD4 signaling in medial edge epithelium, establishing a third major input pathway and showing that IRF6 overexpression can compensate for loss of TGFβ receptor signaling during palatal fusion.","evidence":"Conditional Smad4 and Tgfbr2 knockout mice, Irf6 haploinsufficiency crosses, Irf6 overexpression rescue of p21 and MEE degeneration","pmids":["23406900"],"confidence":"High","gaps":["Whether SMAD4 directly binds the IRF6 promoter or acts through p63 not distinguished","downstream target genes mediating MEE fate beyond p21 not identified"]},{"year":2014,"claim":"Characterization of a disease-associated MCS9.7 enhancer mutation revealed a dual mechanism — simultaneous loss of p63/E47 binding and gain of a Lef1/β-catenin repressor site — explaining how a single nucleotide change could profoundly silence IRF6 and refining understanding of IRF6 cis-regulation.","evidence":"Luciferase reporters in human cells, transgenic mouse lacZ assay, EMSA for p63, E47, and Lef1","pmids":["24442519"],"confidence":"High","gaps":["Whether this dual mechanism operates at other IRF6 enhancers unknown","chromatin-level effects of the mutation not assessed"]},{"year":2014,"claim":"Demonstrating that RIPK4-deficient mice phenocopy IRF6 loss (periderm defects, epithelial fusions) and that kinase-dead RIPK4 fails to rescue IRF6-dependent gastrulation defects in Xenopus identified RIPK4 as the activating kinase for IRF6 and established kinase activity as essential.","evidence":"RIPK4 knockout mice, Xenopus dominant-negative IRF6 with wild-type or kinase-dead RIPK4 rescue","pmids":["25430793"],"confidence":"High","gaps":["Precise phosphorylation sites not yet mapped in this study","direct kinase–substrate interaction not shown biochemically here"]},{"year":2015,"claim":"Mapping RIPK4 phosphorylation of IRF6 to Ser413 and Ser424 and showing that the VWS-associated R412X truncation causes proteasomal IRF6 degradation linked the biochemistry of RIPK4-IRF6 activation to specific disease mutations, explaining both VWS and BPS at the molecular level.","evidence":"Phospho-site mutagenesis, proteasome inhibition, reporter assays with disease-associated mutants","pmids":["25784454"],"confidence":"High","gaps":["Crystal structure of phosphorylated IRF6 not available","whether additional kinases phosphorylate these sites in vivo unknown"]},{"year":2015,"claim":"Placing SNAI2 downstream of IRF6 in TGFβ3-mediated palatal fusion showed that IRF6 can promote epithelial-mesenchymal transition in a specific developmental context, complicating its general characterization as a differentiation/tumor suppressor factor.","evidence":"Palatal shelf organ culture with siRNA knockdown and IRF6 overexpression, EMT marker analysis","pmids":["26240017"],"confidence":"Medium","gaps":["Whether IRF6 directly binds the SNAI2 promoter not demonstrated","relevance of this EMT-promoting activity outside palatal fusion not tested"]},{"year":2015,"claim":"Identifying IRF6 as a regulator of innate immune cytokines (IL-36γ via TLR2/IRAK1, and IL-23p19 via TLR3) in epithelial cells expanded IRF6's function beyond development into barrier immunity, revealing direct promoter regulation of inflammatory mediators.","evidence":"siRNA silencing, promoter reporter assays, TLR agonist stimulation in oral epithelial cells and keratinocytes","pmids":["26819203","26303210"],"confidence":"Medium","gaps":["In vivo immune phenotype of Irf6-deficient epithelial barrier not assessed","genome-wide identification of IRF6 immune target genes not performed"]},{"year":2016,"claim":"Demonstrating that RIPK4 drives CCL5 and CXCL11 expression specifically through IRF6 transactivation unified the RIPK4-IRF6 kinase axis with inflammatory chemokine regulation, bridging the developmental and immune arms of IRF6 function.","evidence":"Overexpression and siRNA silencing of RIPK4 and IRF6, promoter reporter assays in keratinocytes","pmids":["27014863"],"confidence":"Medium","gaps":["Whether RIPK4-IRF6 chemokine axis operates in vivo during infection or inflammation not tested"]},{"year":2016,"claim":"Tissue-specific Irf6 ablation in oral epithelium revealed that IRF6 maintains junctional integrity (restraining RHO GTPase activity), controls salivary gland morphogenesis, and sustains mucosal barrier defense against cariogenic bacteria, extending IRF6's epithelial functions to glandular homeostasis.","evidence":"Oral epithelium-specific Irf6 conditional knockout, RHO GTPase assay, saliva flow measurement, bacterial colonization assay","pmids":["27927890"],"confidence":"High","gaps":["Direct transcriptional targets controlling RHO GTPase activity not identified","whether salivary phenotype is cell-autonomous not fully resolved"]},{"year":2018,"claim":"Showing that HPV16 E6 suppresses IRF6 transcription by degrading p53, which normally occupies the IRF6 promoter, identified p53 as a second transcription factor (alongside p63) directly activating IRF6, and revealed viral exploitation of this axis for immune evasion via IL-1β suppression.","evidence":"ChIP for p53 at IRF6 promoter in cervical cancer tissues, E6 mutants preventing p53 degradation, promoter reporters","pmids":["30089163"],"confidence":"High","gaps":["Relative contributions of p53 versus p63 to IRF6 expression in normal keratinocytes not quantified"]},{"year":2019,"claim":"Multi-omic profiling of IRF6-deficient embryonic skin established that RIPK4 phosphorylation activates IRF6 at bivalent promoters to drive lipid metabolism and tight junction gene programs essential for epidermal barrier formation, providing a comprehensive mechanistic picture of the RIPK4-IRF6 differentiation axis.","evidence":"RNA-seq, ChIP-seq, and ATAC-seq of wild-type versus IRF6-deficient embryonic skin; phospho-site mutagenesis","pmids":["31578523"],"confidence":"High","gaps":["Cofactors recruiting IRF6 to bivalent promoters not identified","whether IRF6 binding resolves bivalency or requires additional chromatin remodelers unknown"]},{"year":2024,"claim":"Discovery that EMT factors ZEB1 and SNAIL epigenetically silence IRF6 during acquired immunotherapy resistance in pancreatic cancer, rendering tumor cells resistant to TNF-α-mediated apoptosis, established a tumor cell-intrinsic immune evasion mechanism and expanded IRF6's tumor suppressor role to immunotherapy response.","evidence":"Mouse PDAC immunotherapy resistance model, RNA-seq, ChIP/epigenetic analysis, TNF-α killing assays","pmids":["38378697"],"confidence":"High","gaps":["Direct IRF6 target genes mediating TNF-α sensitivity not identified","therapeutic potential of restoring IRF6 expression not tested","generalizability beyond pancreatic cancer unknown"]},{"year":null,"claim":"The structural basis of IRF6 activation upon RIPK4 phosphorylation, the identity of cofactors that recruit IRF6 to bivalent chromatin, and the full spectrum of direct genomic targets mediating its immune versus developmental functions remain to be determined.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of IRF6 available","Genome-wide comparison of IRF6 targets in immune versus developmental contexts not performed","Whether IRF6 dimerizes with other IRF family members for specific functions is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,5,10,11,14]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,5]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,5,10,11,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,4,7,9,15,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,7,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11,12,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,17,23]}],"complexes":[],"partners":["RIPK4","TP63","SMAD4","TWIST1","IRAK1","SPECC1L"],"other_free_text":[]},"mechanistic_narrative":"IRF6 is a transcription factor central to epithelial differentiation, morphogenesis, and barrier formation, functioning as a key effector downstream of p63, Notch, and TGFβ/SMAD4 signaling pathways. It is phosphorylated by RIPK4 at Ser413 and Ser424 to activate its transactivation function, whereupon it drives expression of genes controlling lipid metabolism, tight junctions, periderm integrity, and cell cycle exit, while simultaneously promoting proteasome-mediated degradation of p63 to limit keratinocyte proliferative potential [PMID:31578523, PMID:21807998, PMID:25784454]. Loss-of-function mutations cause Van der Woude syndrome and dominant-negative mutations cause popliteal pterygium syndrome, reflecting IRF6's essential role in orofacial and skin development [PMID:12219090]. IRF6 also functions in innate immune signaling by regulating inflammatory cytokines including IL-36γ, CCL5, CXCL11, and IL-1β, and its epigenetic silencing by EMT transcription factors ZEB1/SNAIL in tumor cells confers resistance to TNF-α-mediated apoptosis during immunotherapy [PMID:26819203, PMID:27014863, PMID:38378697]."},"prefetch_data":{"uniprot":{"accession":"O14896","full_name":"Interferon regulatory factor 6","aliases":[],"length_aa":467,"mass_kda":53.1,"function":"Probable DNA-binding transcriptional activator. Key determinant of the keratinocyte proliferation-differentiation switch involved in appropriate epidermal development (By similarity). Plays a role in regulating mammary epithelial cell proliferation (By similarity). May regulate WDR65 transcription (By similarity)","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/O14896/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IRF6","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IRF6","total_profiled":1310},"omim":[{"mim_id":"614259","title":"CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 57; CFAP57","url":"https://www.omim.org/entry/614259"},{"mim_id":"614140","title":"SPERM ANTIGEN WITH CALPONIN HOMOLOGY AND COILED-COIL DOMAINS 1-LIKE; SPECC1L","url":"https://www.omim.org/entry/614140"},{"mim_id":"613857","title":"OROFACIAL CLEFT 13; OFC13","url":"https://www.omim.org/entry/613857"},{"mim_id":"610496","title":"RHO GTPase-ACTIVATING PROTEIN 29; ARHGAP29","url":"https://www.omim.org/entry/610496"},{"mim_id":"608864","title":"OROFACIAL CLEFT 6, SUSCEPTIBILITY TO; OFC6","url":"https://www.omim.org/entry/608864"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":86.6},{"tissue":"skin 1","ntpm":104.1}],"url":"https://www.proteinatlas.org/search/IRF6"},"hgnc":{"alias_symbol":["OFC6","VWS1"],"prev_symbol":["VWS","LPS"]},"alphafold":{"accession":"O14896","domains":[{"cath_id":"1.10.10.10","chopping":"9-112","consensus_level":"high","plddt":86.1837,"start":9,"end":112},{"cath_id":"2.60.200.10","chopping":"214-410_430-444","consensus_level":"high","plddt":90.682,"start":214,"end":444}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14896","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14896-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14896-F1-predicted_aligned_error_v6.png","plddt_mean":73.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IRF6","jax_strain_url":"https://www.jax.org/strain/search?query=IRF6"},"sequence":{"accession":"O14896","fasta_url":"https://rest.uniprot.org/uniprotkb/O14896.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14896/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14896"}},"corpus_meta":[{"pmid":"12219090","id":"PMC_12219090","title":"Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12219090","citation_count":652,"is_preprint":false},{"pmid":"7505800","id":"PMC_7505800","title":"Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7505800","citation_count":622,"is_preprint":false},{"pmid":"30962589","id":"PMC_30962589","title":"Innate immunity to intracellular LPS.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30962589","citation_count":478,"is_preprint":false},{"pmid":"31142822","id":"PMC_31142822","title":"Pushing the envelope: LPS modifications and their consequences.","date":"2019","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31142822","citation_count":381,"is_preprint":false},{"pmid":"27986454","id":"PMC_27986454","title":"Reconstruction of LPS Transfer Cascade Reveals Structural Determinants within LBP, CD14, and TLR4-MD2 for Efficient LPS Recognition and Transfer.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27986454","citation_count":339,"is_preprint":false},{"pmid":"9665271","id":"PMC_9665271","title":"LPS-binding proteins and receptors.","date":"1998","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9665271","citation_count":339,"is_preprint":false},{"pmid":"9182680","id":"PMC_9182680","title":"T cell stimulation in vivo by lipopolysaccharide (LPS).","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9182680","citation_count":260,"is_preprint":false},{"pmid":"17481951","id":"PMC_17481951","title":"Structural biology of the LPS recognition.","date":"2007","source":"International journal of medical microbiology : IJMM","url":"https://pubmed.ncbi.nlm.nih.gov/17481951","citation_count":215,"is_preprint":false},{"pmid":"1375247","id":"PMC_1375247","title":"Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1375247","citation_count":207,"is_preprint":false},{"pmid":"27216281","id":"PMC_27216281","title":"Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation.","date":"2016","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/27216281","citation_count":204,"is_preprint":false},{"pmid":"32087283","id":"PMC_32087283","title":"Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation.","date":"2020","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32087283","citation_count":188,"is_preprint":false},{"pmid":"31805278","id":"PMC_31805278","title":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway.","date":"2019","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31805278","citation_count":172,"is_preprint":false},{"pmid":"11489942","id":"PMC_11489942","title":"Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11489942","citation_count":160,"is_preprint":false},{"pmid":"21982646","id":"PMC_21982646","title":"A conserved Pbx-Wnt-p63-Irf6 regulatory module controls face morphogenesis by promoting epithelial apoptosis.","date":"2011","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/21982646","citation_count":160,"is_preprint":false},{"pmid":"8626747","id":"PMC_8626747","title":"Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626747","citation_count":155,"is_preprint":false},{"pmid":"12538700","id":"PMC_12538700","title":"Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12538700","citation_count":154,"is_preprint":false},{"pmid":"16954198","id":"PMC_16954198","title":"LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: Evidence for LITAF-dependent LPS signaling pathways.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16954198","citation_count":153,"is_preprint":false},{"pmid":"21807998","id":"PMC_21807998","title":"Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21807998","citation_count":141,"is_preprint":false},{"pmid":"28397806","id":"PMC_28397806","title":"Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28397806","citation_count":125,"is_preprint":false},{"pmid":"19109745","id":"PMC_19109745","title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice.","date":"2008","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/19109745","citation_count":125,"is_preprint":false},{"pmid":"7681085","id":"PMC_7681085","title":"Cross-linking of lipopolysaccharide (LPS) to CD14 on THP-1 cells mediated by LPS-binding protein.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7681085","citation_count":125,"is_preprint":false},{"pmid":"10356643","id":"PMC_10356643","title":"A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs).","date":"1999","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/10356643","citation_count":116,"is_preprint":false},{"pmid":"19439425","id":"PMC_19439425","title":"Integration of IRF6 and Jagged2 signalling is essential for controlling palatal adhesion and fusion competence.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19439425","citation_count":116,"is_preprint":false},{"pmid":"26984741","id":"PMC_26984741","title":"Micheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26984741","citation_count":105,"is_preprint":false},{"pmid":"21909072","id":"PMC_21909072","title":"IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/21909072","citation_count":101,"is_preprint":false},{"pmid":"22101278","id":"PMC_22101278","title":"Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects.","date":"2011","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22101278","citation_count":100,"is_preprint":false},{"pmid":"7929195","id":"PMC_7929195","title":"Hemoglobin, a newly recognized lipopolysaccharide (LPS)-binding protein that enhances LPS biological activity.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7929195","citation_count":99,"is_preprint":false},{"pmid":"9228038","id":"PMC_9228038","title":"Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9228038","citation_count":95,"is_preprint":false},{"pmid":"16096995","id":"PMC_16096995","title":"Variation in IRF6 contributes to nonsyndromic cleft lip and palate.","date":"2005","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/16096995","citation_count":95,"is_preprint":false},{"pmid":"30654491","id":"PMC_30654491","title":"Regulated Assembly of LPS, Its Structural Alterations and Cellular Response to LPS Defects.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30654491","citation_count":94,"is_preprint":false},{"pmid":"24272171","id":"PMC_24272171","title":"Lipopolysaccharide (LPS) induces the apoptosis and inhibits osteoblast differentiation through JNK pathway in MC3T3-E1 cells.","date":"2014","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24272171","citation_count":94,"is_preprint":false},{"pmid":"17438386","id":"PMC_17438386","title":"Association between IRF6 and nonsyndromic cleft lip with or without cleft palate in four populations.","date":"2007","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17438386","citation_count":92,"is_preprint":false},{"pmid":"26300543","id":"PMC_26300543","title":"Salidroside attenuates lipopolysaccharide (LPS) induced serum cytokines and depressive-like behavior in mice.","date":"2015","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/26300543","citation_count":84,"is_preprint":false},{"pmid":"11129414","id":"PMC_11129414","title":"LPS and cytokine-activated endothelium.","date":"2000","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11129414","citation_count":81,"is_preprint":false},{"pmid":"17318851","id":"PMC_17318851","title":"Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17318851","citation_count":80,"is_preprint":false},{"pmid":"23406900","id":"PMC_23406900","title":"Smad4-Irf6 genetic interaction and TGFβ-mediated IRF6 signaling cascade are crucial for palatal fusion in mice.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23406900","citation_count":76,"is_preprint":false},{"pmid":"31578523","id":"PMC_31578523","title":"The RIPK4-IRF6 signalling axis safeguards epidermal differentiation and barrier function.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31578523","citation_count":73,"is_preprint":false},{"pmid":"24566933","id":"PMC_24566933","title":"Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation.","date":"2014","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24566933","citation_count":72,"is_preprint":false},{"pmid":"7543094","id":"PMC_7543094","title":"Lipopolysaccharide (LPS) neutralizing peptides reveal a lipid A binding site of LPS binding protein.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7543094","citation_count":69,"is_preprint":false},{"pmid":"11090938","id":"PMC_11090938","title":"Induction of proliferation and cytokine production in human T lymphocytes by lipopolysaccharide (LPS).","date":"2000","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/11090938","citation_count":69,"is_preprint":false},{"pmid":"28355240","id":"PMC_28355240","title":"Optimized Triton X-114 assisted lipopolysaccharide (LPS) removal method reveals the immunomodulatory effect of food proteins.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28355240","citation_count":66,"is_preprint":false},{"pmid":"32527996","id":"PMC_32527996","title":"Lin28A promotes IRF6-regulated aerobic glycolysis in glioma cells by stabilizing SNHG14.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32527996","citation_count":59,"is_preprint":false},{"pmid":"33036869","id":"PMC_33036869","title":"Border Control: Regulating LPS Biogenesis.","date":"2020","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33036869","citation_count":58,"is_preprint":false},{"pmid":"25480336","id":"PMC_25480336","title":"Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury.","date":"2014","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25480336","citation_count":57,"is_preprint":false},{"pmid":"24442519","id":"PMC_24442519","title":"An etiologic regulatory mutation in IRF6 with loss- and gain-of-function effects.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24442519","citation_count":55,"is_preprint":false},{"pmid":"21810964","id":"PMC_21810964","title":"Lipopolysaccharide (LPS) inner-core phosphates are required for complete LPS synthesis and transport to the outer membrane in Pseudomonas aeruginosa PAO1.","date":"2011","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/21810964","citation_count":54,"is_preprint":false},{"pmid":"19275723","id":"PMC_19275723","title":"New insight in LPS antagonist.","date":"2009","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19275723","citation_count":52,"is_preprint":false},{"pmid":"26038568","id":"PMC_26038568","title":"Cell rejuvenation and social behaviors promoted by LPS exchange in myxobacteria.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26038568","citation_count":51,"is_preprint":false},{"pmid":"26303210","id":"PMC_26303210","title":"TLR3 drives IRF6-dependent IL-23p19 expression and p19/EBI3 heterodimer formation in keratinocytes.","date":"2015","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26303210","citation_count":50,"is_preprint":false},{"pmid":"22441700","id":"PMC_22441700","title":"Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes.","date":"2012","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22441700","citation_count":49,"is_preprint":false},{"pmid":"26819203","id":"PMC_26819203","title":"IRF6 Regulates the Expression of IL-36γ by Human Oral Epithelial Cells in Response to Porphyromonas gingivalis.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26819203","citation_count":48,"is_preprint":false},{"pmid":"19734457","id":"PMC_19734457","title":"Association between IRF6 SNPs and oral clefts in West China.","date":"2009","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/19734457","citation_count":47,"is_preprint":false},{"pmid":"26240017","id":"PMC_26240017","title":"IRF6 is the mediator of TGFβ3 during regulation of the epithelial mesenchymal transition and palatal fusion.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26240017","citation_count":46,"is_preprint":false},{"pmid":"36270256","id":"PMC_36270256","title":"Pinostrobin ameliorates lipopolysaccharide (LPS)-induced inflammation and endotoxemia by inhibiting LPS binding to the TLR4/MD2 complex.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36270256","citation_count":43,"is_preprint":false},{"pmid":"23029012","id":"PMC_23029012","title":"Interaction between IRF6 and TGFA genes contribute to the risk of nonsyndromic cleft lip/palate.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029012","citation_count":43,"is_preprint":false},{"pmid":"23084372","id":"PMC_23084372","title":"Adjudin attenuates lipopolysaccharide (LPS)- and ischemia-induced microglial activation.","date":"2012","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/23084372","citation_count":43,"is_preprint":false},{"pmid":"28135711","id":"PMC_28135711","title":"Gelsolin Inhibits the Inflammatory Process Induced by LPS.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28135711","citation_count":42,"is_preprint":false},{"pmid":"25430793","id":"PMC_25430793","title":"A novel RIPK4-IRF6 connection is required to prevent epithelial fusions characteristic for popliteal pterygium syndromes.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25430793","citation_count":41,"is_preprint":false},{"pmid":"18604160","id":"PMC_18604160","title":"IRF6 in development and disease: a mediator of quiescence and differentiation.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18604160","citation_count":38,"is_preprint":false},{"pmid":"22113860","id":"PMC_22113860","title":"MCS9.7 enhancer activity is highly, but not completely, associated with expression of Irf6 and p63.","date":"2011","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/22113860","citation_count":38,"is_preprint":false},{"pmid":"22022450","id":"PMC_22022450","title":"HDAC6 regulates LPS-tolerance in astrocytes.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22022450","citation_count":37,"is_preprint":false},{"pmid":"12040919","id":"PMC_12040919","title":"TLR4 and LPS hyporesponsiveness in humans.","date":"2002","source":"International journal of hygiene and environmental health","url":"https://pubmed.ncbi.nlm.nih.gov/12040919","citation_count":37,"is_preprint":false},{"pmid":"25400741","id":"PMC_25400741","title":"Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25400741","citation_count":34,"is_preprint":false},{"pmid":"30089163","id":"PMC_30089163","title":"Human papillomavirus type 16 antagonizes IRF6 regulation of IL-1β.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/30089163","citation_count":33,"is_preprint":false},{"pmid":"31906130","id":"PMC_31906130","title":"Hydroxytyrosol Decreases LPS- and α-Synuclein-Induced Microglial Activation In Vitro.","date":"2019","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31906130","citation_count":33,"is_preprint":false},{"pmid":"26170061","id":"PMC_26170061","title":"Lack of LCAT reduces the LPS-neutralizing capacity of HDL and enhances LPS-induced inflammation in mice.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26170061","citation_count":33,"is_preprint":false},{"pmid":"29040306","id":"PMC_29040306","title":"Micheliolide suppresses LPS-induced neuroinflammatory responses.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29040306","citation_count":32,"is_preprint":false},{"pmid":"30689861","id":"PMC_30689861","title":"The TFAP2A-IRF6-GRHL3 genetic pathway is conserved in neurulation.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30689861","citation_count":31,"is_preprint":false},{"pmid":"33817486","id":"PMC_33817486","title":"Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.","date":"2021","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/33817486","citation_count":31,"is_preprint":false},{"pmid":"28288940","id":"PMC_28288940","title":"Anti-inflammatory mechanism of lonchocarpine in LPS- or poly(I:C)-induced neuroinflammation.","date":"2017","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/28288940","citation_count":31,"is_preprint":false},{"pmid":"23437199","id":"PMC_23437199","title":"Granulocyte colony stimulating factor induces lipopolysaccharide (LPS) sensitization via upregulation of LPS binding protein in rat.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23437199","citation_count":31,"is_preprint":false},{"pmid":"24818921","id":"PMC_24818921","title":"LPS quantitation procedures.","date":"2014","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/24818921","citation_count":31,"is_preprint":false},{"pmid":"28769044","id":"PMC_28769044","title":"Intercellular Genetic Interaction Between Irf6 and Twist1 during Craniofacial Development.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28769044","citation_count":30,"is_preprint":false},{"pmid":"28357449","id":"PMC_28357449","title":"Myricetin protects cardiomyocytes from LPS-induced injury.","date":"2017","source":"Herz","url":"https://pubmed.ncbi.nlm.nih.gov/28357449","citation_count":30,"is_preprint":false},{"pmid":"12920575","id":"PMC_12920575","title":"Novel mutations in the IRF6 gene for Van der Woude syndrome.","date":"2003","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12920575","citation_count":30,"is_preprint":false},{"pmid":"7890395","id":"PMC_7890395","title":"Prolonged expression of lipopolysaccharide (LPS)-induced inflammatory genes in whole blood requires continual exposure to LPS.","date":"1995","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7890395","citation_count":29,"is_preprint":false},{"pmid":"28945736","id":"PMC_28945736","title":"Rapid functional analysis of computationally complex rare human IRF6 gene variants using a novel zebrafish model.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28945736","citation_count":29,"is_preprint":false},{"pmid":"22002480","id":"PMC_22002480","title":"LPS-binding protein enables intestinal epithelial restitution despite LPS exposure.","date":"2012","source":"Journal of pediatric gastroenterology and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/22002480","citation_count":27,"is_preprint":false},{"pmid":"8524933","id":"PMC_8524933","title":"Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins.","date":"1995","source":"Progress in clinical and biological research","url":"https://pubmed.ncbi.nlm.nih.gov/8524933","citation_count":27,"is_preprint":false},{"pmid":"9733616","id":"PMC_9733616","title":"Pulmonary LPS-binding protein (LBP) upregulation following LPS-mediated injury.","date":"1998","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/9733616","citation_count":25,"is_preprint":false},{"pmid":"20472936","id":"PMC_20472936","title":"ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/20472936","citation_count":25,"is_preprint":false},{"pmid":"38378697","id":"PMC_38378697","title":"Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38378697","citation_count":23,"is_preprint":false},{"pmid":"31943082","id":"PMC_31943082","title":"SPECC1L regulates palate development downstream of IRF6.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31943082","citation_count":23,"is_preprint":false},{"pmid":"33188619","id":"PMC_33188619","title":"Protective Activity of Aβ on Cell Cultures (PC12 and THP-1 after Differentiation) Preincubated with Lipopolysaccharide (LPS).","date":"2020","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33188619","citation_count":23,"is_preprint":false},{"pmid":"30073169","id":"PMC_30073169","title":"LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion.","date":"2018","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30073169","citation_count":22,"is_preprint":false},{"pmid":"17514581","id":"PMC_17514581","title":"Effect of peripherally administered lipopolysaccharide (LPS) on GTP cyclohydrolase I, tetrahydrobiopterin and norepinephrine in the locus coeruleus in mice.","date":"2007","source":"Stress (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/17514581","citation_count":22,"is_preprint":false},{"pmid":"31825181","id":"PMC_31825181","title":"PBX-WNT-P63-IRF6 pathway in nonsyndromic cleft lip and palate.","date":"2019","source":"Birth defects research","url":"https://pubmed.ncbi.nlm.nih.gov/31825181","citation_count":21,"is_preprint":false},{"pmid":"33362762","id":"PMC_33362762","title":"TLR4 Response to LPS Is Reinforced by Urokinase Receptor.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33362762","citation_count":21,"is_preprint":false},{"pmid":"14563359","id":"PMC_14563359","title":"Distinct LPS-induced signals regulate LPS uptake and morphological changes in medfly hemocytes.","date":"2003","source":"Insect biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14563359","citation_count":21,"is_preprint":false},{"pmid":"15013698","id":"PMC_15013698","title":"A novel mutation of the IRF6 gene in an Italian family with Van der Woude syndrome.","date":"2004","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/15013698","citation_count":21,"is_preprint":false},{"pmid":"23949966","id":"PMC_23949966","title":"Search for genetic modifiers of IRF6 and genotype-phenotype correlations in Van der Woude and popliteal pterygium syndromes.","date":"2013","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/23949966","citation_count":21,"is_preprint":false},{"pmid":"32143367","id":"PMC_32143367","title":"BMP-9 Modulates the Hepatic Responses to LPS.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32143367","citation_count":20,"is_preprint":false},{"pmid":"27014863","id":"PMC_27014863","title":"RIPK4 activates an IRF6-mediated proinflammatory cytokine response in keratinocytes.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27014863","citation_count":20,"is_preprint":false},{"pmid":"27927890","id":"PMC_27927890","title":"Massively Increased Caries Susceptibility in an Irf6 Cleft Lip/Palate Model.","date":"2016","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/27927890","citation_count":20,"is_preprint":false},{"pmid":"14577847","id":"PMC_14577847","title":"Role of interferons in LPS hypersensitivity.","date":"2003","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/14577847","citation_count":19,"is_preprint":false},{"pmid":"12889008","id":"PMC_12889008","title":"Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production.","date":"2003","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/12889008","citation_count":19,"is_preprint":false},{"pmid":"22366192","id":"PMC_22366192","title":"The role of Irf6 in tooth epithelial invagination.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22366192","citation_count":19,"is_preprint":false},{"pmid":"11746036","id":"PMC_11746036","title":"Possible relationship between the van der Woude syndrome (vWS) locus and nonsyndromic cleft lip with or without cleft palate (NSCL/P).","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11746036","citation_count":18,"is_preprint":false},{"pmid":"26161746","id":"PMC_26161746","title":"IRF6 Is Involved in the Regulation of Cell Proliferation and Transformation in MCF10A Cells Downstream of Notch Signaling.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26161746","citation_count":18,"is_preprint":false},{"pmid":"25784454","id":"PMC_25784454","title":"Disease-associated mutations in IRF6 and RIPK4 dysregulate their signalling functions.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25784454","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50271,"output_tokens":5949,"usd":0.120024},"stage2":{"model":"claude-opus-4-6","input_tokens":9603,"output_tokens":3686,"usd":0.210248},"total_usd":0.330272,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"IRF6 encodes a transcription factor with a helix-turn-helix DNA-binding domain and a protein-binding domain; loss-of-function (haploinsufficiency) mutations cause Van der Woude syndrome and dominant-negative mutations cause popliteal pterygium syndrome, establishing IRF6 as required for orofacial and skin development. Expression analyses showed high Irf6 mRNA in medial edge epithelium of fusing palate, tooth buds, hair follicles, genitalia, and skin.\",\n      \"method\": \"Mutation identification by sequencing, expression analysis by in situ hybridization\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — seminal loss-of-function genetics with expression data, widely replicated\",\n      \"pmids\": [\"12219090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A conserved Pbx-Wnt-p63-Irf6 regulatory module controls midfacial ectoderm development; Pbx proteins bind a midfacial regulatory element to drive Wnt9b-Wnt3 expression, which in turn regulates p63 and thereby Irf6, promoting epithelial apoptosis required for facial process fusion. Loss of Pbx in cephalic ectoderm suppresses midfacial apoptosis and causes cleft lip/palate, rescued by ectopic Wnt expression.\",\n      \"method\": \"Conditional knockout mice, ChIP, transgenic rescue experiments\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with ChIP and in vivo rescue, moderate evidence\",\n      \"pmids\": [\"21982646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF6 acts as a tumor suppressor in squamous cell carcinoma (SCC): it is transcriptionally activated by p63 and induces proteasome-mediated downregulation of p63, limiting keratinocyte proliferative potential. ChIP-seq and expression profiling identified direct IRF6 target genes regulating cell cycle, differentiation, adhesion, and cell-cell contact. IRF6 reintroduction into SCC cells strongly inhibits cell growth and invasiveness.\",\n      \"method\": \"ChIP-seq, siRNA knockdown, gene expression profiling, in vitro invasion assays, promoter methylation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP-seq, expression profiling, functional assays) in a single study\",\n      \"pmids\": [\"21807998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF6 is a primary Notch transcriptional target in keratinocytes; Notch activation induces IRF6 expression, and IRF6 is required for the pro-differentiation and tumor suppressive effects of Notch signaling. IRF6 downmodulation counteracts keratinocyte differentiation in vitro and in vivo and promotes ras-induced tumor formation.\",\n      \"method\": \"Reporter assays, siRNA knockdown, in vivo differentiation assays, tumor formation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with in vivo validation\",\n      \"pmids\": [\"21909072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IRF6 and the Notch ligand Jagged2 function in convergent molecular pathways to control oral epithelial differentiation and periderm formation; IRF6 is essential for maintaining oral periderm integrity, spatiotemporal regulation of which determines appropriate palatal adhesion. Loss of Irf6 in mice leads to abnormal oral epithelial differentiation and pathological adhesion between palatal shelves and tongue.\",\n      \"method\": \"Mouse knockout analysis, tissue histology, in situ hybridization, genetic interaction studies\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout with defined cellular and molecular phenotype, replicated findings\",\n      \"pmids\": [\"19439425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RIPK4 kinase phosphorylates IRF6 at Ser413 and Ser424, priming IRF6 for transcriptional activation. IRF6 and RIPK4 regulate overlapping biological processes in epidermal differentiation. IRF6 was enriched at bivalent promoters and its deficiency caused defective expression of genes involved in lipid metabolism and tight junction formation, resulting in abnormal stratum corneum lipid composition and severe epidermal barrier defect.\",\n      \"method\": \"RNA-seq, ChIP-seq, ATAC-seq of wild-type and IRF6-deficient mouse embryo skin, phosphorylation site mutagenesis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multi-omic approach with mutagenesis and in vivo validation\",\n      \"pmids\": [\"31578523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RIPK4-deficient mice display epithelial fusions associated with abnormal periderm development and aberrant ectopic E-cadherin localization on the apical peridermal membrane. In Xenopus, IRF6 controls RIPK4 expression, and wild-type but not kinase-dead RIPK4 rescues gastrulation defects caused by dominant-negative IRF6. RIPK4 plays a role in cortical actin cytoskeleton organization in mouse epidermis and human HaCaT epithelial cells.\",\n      \"method\": \"Mouse and Xenopus knockdown/overexpression, rescue experiments with kinase-dead RIPK4, immunofluorescence for E-cadherin and actin\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple species, epistasis experiments, kinase-dead rescue distinguishes mechanism\",\n      \"pmids\": [\"25430793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TGFβ signaling via SMAD4 regulates IRF6 expression and MEE fate during palatal fusion. Haploinsufficiency of Irf6 in mice with Smad4 deletion in basal epithelium results in MEE persistence; overexpression of Irf6 rescues p21 expression and MEE degeneration in Tgfbr2-deficient mice, placing IRF6 downstream of TGFβ/SMAD4 in palatal fusion.\",\n      \"method\": \"Conditional knockout mice, genetic epistasis, in vivo Irf6 overexpression rescue experiments, p21 expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis confirmed with rescue experiment in two genotypes\",\n      \"pmids\": [\"23406900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF6 phosphorylation by RIPK4 at Ser413 and Ser424 induces IRF6 transactivation function; the VWS-associated p.Arg412X truncation causes rapid proteasome-dependent IRF6 degradation and prevents RIPK4-induced transactivation. The BPS-associated RIPK4 p.Ser376X mutation impairs RIPK4 induction of IRF6 transactivator function and also inhibits RIPK4-mediated β-catenin stabilization.\",\n      \"method\": \"Transfection with mutant constructs, proteasome inhibition assay, reporter assays for transactivation, co-expression experiments\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with functional readouts for both IRF6 and RIPK4 disease mutations\",\n      \"pmids\": [\"25784454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TGFβ3 increases IRF6 expression, which subsequently upregulates SNAI2 (an EMT regulator) and downregulates epithelial markers (E-cadherin, Plakophilin, ZO-1), promoting epithelial-mesenchymal transition during palatal fusion. Blocking SNAI2 delays palatal fusion and abolishes the IRF6 rescue effect, placing SNAI2 downstream of IRF6 in TGFβ3-mediated palatogenesis.\",\n      \"method\": \"Palatal shelf organ culture, siRNA knockdown, ectopic IRF6 overexpression, immunofluorescence for EMT markers\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ex vivo system with overexpression and knockdown, single lab\",\n      \"pmids\": [\"26240017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF6 acts downstream of IRAK1 (IL-1R-associated kinase 1) in TLR2 signaling to stimulate IL-36γ expression in human oral epithelial cells in response to Porphyromonas gingivalis. Gene silencing and promoter assays demonstrated IRF6 directly regulates IL-36γ promoter activity.\",\n      \"method\": \"siRNA gene silencing, gene promoter reporter assays, TLR2 agonist stimulation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — epistasis and promoter assays from single lab\",\n      \"pmids\": [\"26819203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF6 regulates TLR3-dependent IL-23p19 expression in human keratinocytes; IRF6 silencing enhances poly(IC)-inducible IFN-β and inhibits IL-23p19 expression. Overexpression of IRF6 increases IL-23p19 promoter activity but inhibits IFN-β promoter activity. IL-23p19 and EBI3 interact (forming a novel heterodimer) as shown by co-immunoprecipitation and proximity ligation assays.\",\n      \"method\": \"siRNA silencing, reporter assays, co-immunoprecipitation, proximity ligation assay\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — multiple methods from single lab, IP confirmed by proximity ligation\",\n      \"pmids\": [\"26303210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RIPK4 and IRF6 function as a signaling axis in keratinocytes to regulate proinflammatory cytokine expression; RIPK4 overexpression specifically induces CCL5 and CXCL11 through IRF6-mediated transactivation of their promoters. Gene silencing confirmed that inducible CCL5 and CXCL11 expression requires both RIPK4 and IRF6.\",\n      \"method\": \"Overexpression, siRNA silencing, gene reporter assays\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — consistent with RIPK4-IRF6 axis, reporter assays plus knockdown, single lab\",\n      \"pmids\": [\"27014863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A mutation (350dupA) in the conserved IRF6 enhancer element MCS9.7 abrogates p63 and E47 binding to overlapping cis-motifs and disrupts enhancer activity; additionally, the mutation creates a CAAAGT Lef1 binding site that enables Lef1/β-Catenin to repress MCS9.7 enhancer activity, demonstrating a dual loss- and gain-of-function mechanism at the IRF6 regulatory element.\",\n      \"method\": \"Luciferase reporter assays in human cell cultures, transgenic mouse lacZ reporter assay, EMSA/binding assays for p63, E47, and Lef1\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — reporter assays plus transgenic mouse validation plus binding assays\",\n      \"pmids\": [\"24442519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HPV16 E6 oncoprotein inhibits IRF6 transcription by degrading p53, which normally binds the IRF6 promoter to drive its expression. IRF6 in turn regulates IL-1β promoter activity in human keratinocytes. HPV16 thus exploits p53 degradation to suppress IRF6 and block IL-1β production as an immune evasion mechanism.\",\n      \"method\": \"siRNA against E6, E6 point mutants preventing p53 degradation, ChIP for p53 at IRF6 promoter in cervical cancer tissues, IRF6 promoter reporter assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in patient tissues plus mutant E6 rescue plus reporter assays\",\n      \"pmids\": [\"30089163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Over-expression of Irf6 in mice causes exencephaly by suppressing Tfap2a and Grhl3 expression; conversely, loss of Irf6 reduces Tfap2a and Grhl3 in tail tissues and causes a curly tail phenotype, establishing Irf6 within a Tfap2a-Irf6-Grhl3 genetic pathway conserved in both orofacial and neural tube morphogenesis.\",\n      \"method\": \"Irf6 overexpression and loss-of-function mouse models, expression analysis of Tfap2a and Grhl3, human spina bifida sequencing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with expression data, bidirectional manipulation\",\n      \"pmids\": [\"30689861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Loss of Irf6 causes craniosynostosis and mandibular hypoplasia; Irf6 and Twist1 interact genetically (double heterozygotes have severe mandibular hypoplasia/agnathia), with reduced EDN1 and downstream DLX5, DLX6, HAND2 expression in mesenchymal cells. Exogenous EDN1 peptides partially rescue Meckel's cartilage abnormalities, and partial rescue also occurs with p53 haploinsufficiency.\",\n      \"method\": \"Double heterozygous mouse crosses, spatiotemporal expression analysis, mandibular explant treatment with EDN1, p53 genetic rescue\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic interaction with molecular pathway readouts and partial rescue\",\n      \"pmids\": [\"28769044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EMT transcription factors ZEB1 and SNAIL epigenetically and transcriptionally silence IRF6 during acquired resistance to immunotherapy in pancreatic ductal adenocarcinoma. IRF6 silencing renders tumor cells less sensitive to TNF-α-mediated pro-apoptotic effects, establishing a tumor cell-intrinsic mechanism of resistance distinct from immune evasion.\",\n      \"method\": \"Mouse PDAC immunotherapy resistance model, RNA-seq, ChIP/epigenetic analysis, functional TNF-α killing assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic model with multiple orthogonal methods and in vivo relevance\",\n      \"pmids\": [\"38378697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Irf6 mutant mice show evagination (rather than invagination) of incisor epithelium similar to Ikkα mutants, with upregulation of canonical Wnt signaling in evaginated incisor epithelium; IRF6 regulates epithelial invagination in an NF-κB-independent manner.\",\n      \"method\": \"Irf6 mouse mutant analysis, in situ hybridization, immunohistochemistry for Wnt pathway components and NF-κB\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout phenotype with molecular pathway analysis, single lab\",\n      \"pmids\": [\"22366192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SPECC1L expression is drastically reduced in Irf6 mutant palatal shelves, and SPECC1L deficiency causes periderm layer abnormalities similar to Irf6 hypomorphic mutants, placing SPECC1L downstream of IRF6 in palatogenesis. SPECC1L mutations that disrupt microtubule association are linked to syndromic CL/P.\",\n      \"method\": \"Irf6 mutant mouse expression analysis, conditional Specc1l knockout mouse, epistasis by genetic cross, immunofluorescence\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — expression epistasis in mutant background confirmed by genetic cross\",\n      \"pmids\": [\"31943082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF6 was identified as a binding partner of maspin in mammary epithelial cells; IRF6 functions synergistically with maspin to regulate mammary epithelial cell differentiation by acting on the cell cycle, promoting exit from the cell cycle and entry into G0 quiescence.\",\n      \"method\": \"Protein interaction studies, cell cycle analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — review/perspective with limited primary experimental detail provided in abstract\",\n      \"pmids\": [\"18604160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Conditional ablation of Irf6 in late embryonic oral epithelium results in dysplastic salivary glands with disrupted epithelial junctional complexes (associated with elevated RHO GTPase activation), increased salivary cell proliferation, reduced saliva flow and buffering capacity, decreased CCL27 expression, and increased colonization by cariogenic bacteria.\",\n      \"method\": \"Conditional Irf6 knockout mouse (oral epithelium-specific), histology, RHO GTPase activity assay, saliva flow measurement, bacterial colonization assay\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific knockout with multiple molecular and functional readouts\",\n      \"pmids\": [\"27927890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Human IRF6 missense variant protein function can be assessed by ability to rescue the irf6-/- periderm rupture phenotype in zebrafish via mRNA microinjection; many variants predicted computationally to be loss-of-function retained partial or full protein function, enabling grouping into wild-type function, reduced function, and complete loss-of-function categories.\",\n      \"method\": \"Zebrafish irf6-/- rescue with human IRF6 variant mRNA microinjection, mRNA dosage titration\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo functional assay in zebrafish model with dosage titration\",\n      \"pmids\": [\"28945736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Lin28A stabilizes lncRNA SNHG14, which promotes IRF6 mRNA degradation by targeting its 3' UTR via STAU1-mediated mRNA decay; this reduces IRF6 expression and consequently relieves IRF6-mediated transcriptional repression of PKM2 and GLUT1, thereby promoting aerobic glycolysis in glioma cells.\",\n      \"method\": \"RNA stability assays, siRNA knockdown, mRNA interaction assays, xenograft tumor models, ChIP/promoter assays for PKM2 and GLUT1\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — multiple methods but complex indirect regulatory cascade; single lab\",\n      \"pmids\": [\"32527996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF6 is involved in cell proliferation and transformation in MCF10A breast epithelial cells downstream of Notch signaling; ΔNp63 downregulation by Notch contributes to IRF6 expression, and IRF6 abrogation impairs Notch-induced proliferation and transformation, demonstrating a context-dependent role for IRF6 as a positive regulator of proliferation downstream of Notch in these cells.\",\n      \"method\": \"siRNA knockdown, Notch activation, proliferation and transformation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, knockdown with proliferation phenotype; context-specific result\",\n      \"pmids\": [\"26161746\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IRF6 is a transcription factor that is activated downstream of p63 (via the MCS9.7 enhancer), Notch, and TGFβ/SMAD4 signaling; it is phosphorylated by RIPK4 at Ser413/424 to prime its transactivation function, enabling IRF6 to drive keratinocyte and epithelial differentiation programs (including lipid metabolism, tight junction, and periderm gene expression), regulate cell cycle exit, suppress EMT-driven tumor cell resistance, and control inflammatory cytokine production (IL-36γ, CCL5, CXCL11, IL-1β), while a reciprocal feedback loop whereby IRF6 induces proteasome-mediated p63 degradation limits keratinocyte proliferative potential.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IRF6 is a transcription factor central to epithelial differentiation, morphogenesis, and barrier formation, functioning as a key effector downstream of p63, Notch, and TGFβ/SMAD4 signaling pathways. It is phosphorylated by RIPK4 at Ser413 and Ser424 to activate its transactivation function, whereupon it drives expression of genes controlling lipid metabolism, tight junctions, periderm integrity, and cell cycle exit, while simultaneously promoting proteasome-mediated degradation of p63 to limit keratinocyte proliferative potential [PMID:31578523, PMID:21807998, PMID:25784454]. Loss-of-function mutations cause Van der Woude syndrome and dominant-negative mutations cause popliteal pterygium syndrome, reflecting IRF6's essential role in orofacial and skin development [PMID:12219090]. IRF6 also functions in innate immune signaling by regulating inflammatory cytokines including IL-36γ, CCL5, CXCL11, and IL-1β, and its epigenetic silencing by EMT transcription factors ZEB1/SNAIL in tumor cells confers resistance to TNF-α-mediated apoptosis during immunotherapy [PMID:26819203, PMID:27014863, PMID:38378697].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying the causative gene for Van der Woude and popliteal pterygium syndromes established that a member of the IRF transcription factor family has a non-immune, developmental role in orofacial and skin morphogenesis.\",\n      \"evidence\": \"Mutation screening and in situ hybridization in affected families and mouse embryos\",\n      \"pmids\": [\"12219090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DNA-binding targets unknown\", \"mechanism of action in epithelial differentiation uncharacterized\", \"post-translational regulation unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that Irf6 knockout mice have defective oral periderm integrity and pathological epithelial adhesions defined the cellular basis of IRF6's role in palatogenesis — maintaining a specialized surface epithelium (periderm) that prevents inappropriate tissue fusion.\",\n      \"evidence\": \"Irf6 knockout mouse phenotyping, histology, and genetic interaction with Jagged2\",\n      \"pmids\": [\"19439425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating periderm formation not identified\", \"relationship between IRF6 and Notch pathway only inferred from parallel phenotypes\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Three studies converged to place IRF6 within interconnected signaling cascades: a Pbx–Wnt–p63–Irf6 module controlling midfacial morphogenesis, Notch signaling directly inducing IRF6 for keratinocyte differentiation and tumor suppression, and a reciprocal feedback loop in which p63 activates IRF6, which then triggers proteasomal p63 degradation to enforce cell cycle exit.\",\n      \"evidence\": \"Conditional knockout mice with ChIP and rescue (Pbx–Wnt); siRNA knockdown with in vivo differentiation and tumor assays (Notch); ChIP-seq, expression profiling, and invasion assays in SCC cells (p63 feedback)\",\n      \"pmids\": [\"21982646\", \"21909072\", \"21807998\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect Notch regulation of IRF6 promoter not fully resolved\", \"genome-wide target overlap between Notch-driven and p63-driven IRF6 programs not compared\", \"structural basis of IRF6–proteasome coupling to p63 degradation unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetic epistasis and rescue experiments placed IRF6 downstream of TGFβ/SMAD4 signaling in medial edge epithelium, establishing a third major input pathway and showing that IRF6 overexpression can compensate for loss of TGFβ receptor signaling during palatal fusion.\",\n      \"evidence\": \"Conditional Smad4 and Tgfbr2 knockout mice, Irf6 haploinsufficiency crosses, Irf6 overexpression rescue of p21 and MEE degeneration\",\n      \"pmids\": [\"23406900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SMAD4 directly binds the IRF6 promoter or acts through p63 not distinguished\", \"downstream target genes mediating MEE fate beyond p21 not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Characterization of a disease-associated MCS9.7 enhancer mutation revealed a dual mechanism — simultaneous loss of p63/E47 binding and gain of a Lef1/β-catenin repressor site — explaining how a single nucleotide change could profoundly silence IRF6 and refining understanding of IRF6 cis-regulation.\",\n      \"evidence\": \"Luciferase reporters in human cells, transgenic mouse lacZ assay, EMSA for p63, E47, and Lef1\",\n      \"pmids\": [\"24442519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this dual mechanism operates at other IRF6 enhancers unknown\", \"chromatin-level effects of the mutation not assessed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that RIPK4-deficient mice phenocopy IRF6 loss (periderm defects, epithelial fusions) and that kinase-dead RIPK4 fails to rescue IRF6-dependent gastrulation defects in Xenopus identified RIPK4 as the activating kinase for IRF6 and established kinase activity as essential.\",\n      \"evidence\": \"RIPK4 knockout mice, Xenopus dominant-negative IRF6 with wild-type or kinase-dead RIPK4 rescue\",\n      \"pmids\": [\"25430793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise phosphorylation sites not yet mapped in this study\", \"direct kinase–substrate interaction not shown biochemically here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping RIPK4 phosphorylation of IRF6 to Ser413 and Ser424 and showing that the VWS-associated R412X truncation causes proteasomal IRF6 degradation linked the biochemistry of RIPK4-IRF6 activation to specific disease mutations, explaining both VWS and BPS at the molecular level.\",\n      \"evidence\": \"Phospho-site mutagenesis, proteasome inhibition, reporter assays with disease-associated mutants\",\n      \"pmids\": [\"25784454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of phosphorylated IRF6 not available\", \"whether additional kinases phosphorylate these sites in vivo unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placing SNAI2 downstream of IRF6 in TGFβ3-mediated palatal fusion showed that IRF6 can promote epithelial-mesenchymal transition in a specific developmental context, complicating its general characterization as a differentiation/tumor suppressor factor.\",\n      \"evidence\": \"Palatal shelf organ culture with siRNA knockdown and IRF6 overexpression, EMT marker analysis\",\n      \"pmids\": [\"26240017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether IRF6 directly binds the SNAI2 promoter not demonstrated\", \"relevance of this EMT-promoting activity outside palatal fusion not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying IRF6 as a regulator of innate immune cytokines (IL-36γ via TLR2/IRAK1, and IL-23p19 via TLR3) in epithelial cells expanded IRF6's function beyond development into barrier immunity, revealing direct promoter regulation of inflammatory mediators.\",\n      \"evidence\": \"siRNA silencing, promoter reporter assays, TLR agonist stimulation in oral epithelial cells and keratinocytes\",\n      \"pmids\": [\"26819203\", \"26303210\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo immune phenotype of Irf6-deficient epithelial barrier not assessed\", \"genome-wide identification of IRF6 immune target genes not performed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that RIPK4 drives CCL5 and CXCL11 expression specifically through IRF6 transactivation unified the RIPK4-IRF6 kinase axis with inflammatory chemokine regulation, bridging the developmental and immune arms of IRF6 function.\",\n      \"evidence\": \"Overexpression and siRNA silencing of RIPK4 and IRF6, promoter reporter assays in keratinocytes\",\n      \"pmids\": [\"27014863\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether RIPK4-IRF6 chemokine axis operates in vivo during infection or inflammation not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Tissue-specific Irf6 ablation in oral epithelium revealed that IRF6 maintains junctional integrity (restraining RHO GTPase activity), controls salivary gland morphogenesis, and sustains mucosal barrier defense against cariogenic bacteria, extending IRF6's epithelial functions to glandular homeostasis.\",\n      \"evidence\": \"Oral epithelium-specific Irf6 conditional knockout, RHO GTPase assay, saliva flow measurement, bacterial colonization assay\",\n      \"pmids\": [\"27927890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets controlling RHO GTPase activity not identified\", \"whether salivary phenotype is cell-autonomous not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing that HPV16 E6 suppresses IRF6 transcription by degrading p53, which normally occupies the IRF6 promoter, identified p53 as a second transcription factor (alongside p63) directly activating IRF6, and revealed viral exploitation of this axis for immune evasion via IL-1β suppression.\",\n      \"evidence\": \"ChIP for p53 at IRF6 promoter in cervical cancer tissues, E6 mutants preventing p53 degradation, promoter reporters\",\n      \"pmids\": [\"30089163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of p53 versus p63 to IRF6 expression in normal keratinocytes not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multi-omic profiling of IRF6-deficient embryonic skin established that RIPK4 phosphorylation activates IRF6 at bivalent promoters to drive lipid metabolism and tight junction gene programs essential for epidermal barrier formation, providing a comprehensive mechanistic picture of the RIPK4-IRF6 differentiation axis.\",\n      \"evidence\": \"RNA-seq, ChIP-seq, and ATAC-seq of wild-type versus IRF6-deficient embryonic skin; phospho-site mutagenesis\",\n      \"pmids\": [\"31578523\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors recruiting IRF6 to bivalent promoters not identified\", \"whether IRF6 binding resolves bivalency or requires additional chromatin remodelers unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that EMT factors ZEB1 and SNAIL epigenetically silence IRF6 during acquired immunotherapy resistance in pancreatic cancer, rendering tumor cells resistant to TNF-α-mediated apoptosis, established a tumor cell-intrinsic immune evasion mechanism and expanded IRF6's tumor suppressor role to immunotherapy response.\",\n      \"evidence\": \"Mouse PDAC immunotherapy resistance model, RNA-seq, ChIP/epigenetic analysis, TNF-α killing assays\",\n      \"pmids\": [\"38378697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IRF6 target genes mediating TNF-α sensitivity not identified\", \"therapeutic potential of restoring IRF6 expression not tested\", \"generalizability beyond pancreatic cancer unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of IRF6 activation upon RIPK4 phosphorylation, the identity of cofactors that recruit IRF6 to bivalent chromatin, and the full spectrum of direct genomic targets mediating its immune versus developmental functions remain to be determined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of IRF6 available\", \"Genome-wide comparison of IRF6 targets in immune versus developmental contexts not performed\", \"Whether IRF6 dimerizes with other IRF family members for specific functions is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 5, 10, 11, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 5, 10, 11, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 4, 7, 9, 15, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 12, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 17, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"RIPK4\",\n      \"TP63\",\n      \"SMAD4\",\n      \"TWIST1\",\n      \"IRAK1\",\n      \"SPECC1L\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}